Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Arcadia Biosciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
3.19
4.03
1.46
1.17
8.03
6.78
7.42
4.45
5.05
4.86
Cost of revenue
0.9
0.28
5.2
8.71
6.1
2.17
2.96
3.1
Gross profit
2.29
3.74
2.84
-1.93
1.32
2.28
2.08
1.76
Research and development
8.66
7.41
6.07
7.1
7.96
3.89
1.51
0.06
0.05
0.01
Selling, general and administrative
12.3
10.7
11.6
13.6
16.5
22.9
15
8.23
9.64
7
Selling and marketing
0.2
0.05
Operating expenses
21.8
18.3
18.3
20.6
20.8
Operating income
-18.6
-14.3
-16.9
-19.4
-12.8
-35.5
-14
-6.1
-3.65
-2.5
Interest expense
1.32
0.75
0.01
0.05
0.02
Other non-operating income
0.34
0.28
0.39
0.47
0.74
10.1
0.01
0.05
0.03
2.31
Pre-tax income
-19.6
-15.7
-13.5
-28.9
-6.15
-16.1
-10.8
-5.32
-4.31
-2.33
Income tax
0.03
0.03
0.01
0
-0.12
0
0.01
0.01
0.01
0.01
Net income to minority interests
-0.07
-1.37
-1.47
-0.24
-0.01
0
Net income
-19.6
-15.7
-13.5
-28.8
-4.66
-14.7
-15.4
-14
-7.04
-2.34
EBITDA
-18.3
-14
-16.7
-19.2
-12.1
-34.6
-13.6
-5.99
-3.59
-2.47
EPS, basic
-353.49
-290.78
-142.99
-180.94
-18.77
-27.56
-25.65
-11.29
-5.17
-1.71
EPS, diluted
-353.49
-290.78
-142.99
-180.94
-18.77
-27.56
-25.65
-11.29
-5.17
-1.71
Shares, basic (weighted)
0.06
0.05
0.09
0.16
0.25
0.53
0.6
1.24
1.36
1.37
Shares, diluted (weighted)
0.06
0.05
0.09
0.16
0.25
0.53
0.6
1.24
1.36
1.37
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
2.01
9.13
12
8.42
14
28.7
20.6
6.52
4.24
0.26
Short-term investments
48.5
3.9
9.83
16.9
11.6
0
5.12
0
4.3
Receivables
0.35
1.23
0.17
0.6
1.41
1.37
Inventory
0.25
0.23
0.18
1.79
3.81
4.43
2.32
0.84
0.9
1.21
Other current assets
0.88
0.56
0.7
0.71
0.81
0.9
0.8
0.81
0.93
0.16
Total current assets
52.2
15
22.9
28.4
31.7
35.4
25.4
15
9.24
6.36
Property, plant and equipment
0.51
0.3
0.4
1.8
3.54
2.29
0.68
0.07
0.04
0.01
Lease right-of-use assets
1.96
5.83
3.08
1.85
0.79
0.14
0
Goodwill
0.41
Intangible assets
0.37
0.48
0.04
0.04
0.04
0.04
Long-term investments
2.5
Other non-current assets
0.02
0.06
0.01
0.01
0.02
0.18
0.17
0.16
0.09
0.14
Total assets
56.6
16.6
24
32.6
47.3
43.9
28.9
19.7
13.5
6.55
Accounts payable
0.22
0.37
0.29
0.49
0.73
1.41
0.91
0.49
0.7
1.45
Accrued liabilities
1.33
0.81
1.1
1.29
1.49
1.61
1.37
1.12
0.96
0.11
Deferred revenue
0.74
1
0.1
0.04
0.01
Short-term debt
0
0.02
1.14
0
Total current liabilities
3.13
3.53
3.05
5.71
6.31
5.04
4.21
3.59
2.56
2.06
Long-term debt
25.1
0.11
2.11
0
Lease liabilities
1.5
5.39
2.22
1.01
0.16
0
Other non-current liabilities
3
3
3.07
2
2.28
2.07
2
2
2
0
Total liabilities
34.4
8.56
11.2
24.2
18.8
12.7
8.02
7
7.29
2.41
Total debt
25.1
0
0
0.11
2.11
0
Paid-in capital
174
175
191
215
239
258
279
285
285
285
Retained earnings
-152
-167
-178
-207
-212
-226
-258
-272
-279
-281
Other comprehensive income
-0.02
-0
0
0
0.1
0
Shareholders' equity
22.2
8.01
12.8
7.71
27.7
31.1
21
12.8
6.22
Minority interests
0.62
0.83
0.1
-0.13
-0.14
0
Total equity
22.2
8.01
12.8
8.33
28.6
31.2
20.9
12.7
6.22
4.14
Total liabilities and equity
56.6
16.6
24
32.6
47.3
43.9
28.9
19.7
13.5
6.55
Shares outstanding
0.06
0.05
0.12
0.22
0.34
0.55
0.62
1.29
1.36
1.37
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-19.6
-15.7
-13.5
-28.9
-6.03
-16.1
-15.6
-14
-7.04
-2.34
Depreciation and amortization
0.3
0.28
0.15
0.19
0.63
0.93
0.44
0.11
0.06
0.03
Stock-based compensation
1.06
1.47
1.55
2.29
2.04
1.54
1.11
0.72
0.51
0.23
Deferred income tax
0
0
0
0
-0.11
0
0
0
0
0
Change in receivables
0.36
-0.88
1.07
-0.44
-1.12
-0.04
0.59
0.18
-0.76
0.17
Change in inventory
0.58
0.18
0.16
-1.54
-9.75
-2.38
1.12
-2.42
0.55
-0.31
Change in payables
-0.02
0.09
0.18
2.1
-0.58
-0.37
-0.76
-0.52
-0.3
-0.4
Cash from operations
-17.1
-14
-13.6
-17.2
-30.2
-25.9
-14
-15.3
-9.63
-4.74
Capital expenditures
-0.23
-0.08
-0.25
-1.48
-2.34
-1.01
-0.07
-0.01
-0.02
0
Acquisitions
-0.5
-4.25
0
Purchases of investments
-41.4
-19.4
-29.9
-28.4
-1.29
0
-7.53
0
Sales and maturities of investments
36.3
66.7
24.2
21.5
18.3
21.8
0
Cash from investing
-5.3
47.2
-5.98
-8.37
17.3
16.6
1.42
-4.34
7.34
0.75
Stock issued
0.44
0.02
0.97
0.02
0.05
0.04
0.01
Cash from financing
0.4
-26.1
22.5
22
20.6
21.9
4.52
5.51
0.01
0.01
Net change in cash
-22
7.11
2.87
-3.58
7.63
12.6
-8.04
-14.1
-2.28
-3.98
Free cash flow
-17.3
-14
-13.9
-18.7
-32.6
-26.9
-14
-15.3
-9.64
-4.74
Interest paid
1.03
0.75
0
0.01
0.03
0
0
Income taxes paid
0.03
0
0.03
0
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.31 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
34.6%
Gross profit / revenue.
Operating margin
-80.2%
Operating income / revenue.
EBITDA margin
-79.9%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-234.5%
Net income / revenue.
Operating cash flow margin
-52.6%
Cash from operations / revenue.
Return on assets (ROA)
-188.9%
Net income / average total assets.
SG&A / revenue
114.7%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
2.1%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
0.3%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-3.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-13.2%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-9.6%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-15.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
10.1%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-9.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-51.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-39.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-32.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
31.7%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
40.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.49x
Current assets / current liabilities.
Quick ratio
2.54x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
2.54x
(Cash + short-term investments) / current liabilities.
Liabilities / assets
89.3%
Total liabilities / total assets.
Working capital
$4.1M
Current assets - current liabilities.
Goodwill and intangibles / assets
0.7%
(Goodwill + intangible assets) / total assets.
Efficiency
Metric
Value
How it is calculated
Asset turnover
0.81x
Revenue / average total assets.
Inventory turnover
3.34x
Cost of revenue / average inventory.
Days inventory
109 days
365 x average inventory / cost of revenue.
Days payables
163 days
365 x average accounts payable / cost of revenue.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$3.72
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Market cap + total debt - cash - short-term investments.
P/S
0.16x
Market cap / revenue.
Earnings yield
-1,500.0%
Net income / market cap (the inverse of P/E).
What was Arcadia Biosciences, Inc.'s revenue in fiscal 2025?
Arcadia Biosciences, Inc. reported revenue of $4.9M for fiscal 2025, 3.7% lower than the year before.
Was Arcadia Biosciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $2.3M.
How much free cash flow did Arcadia Biosciences, Inc. generate in fiscal 2025?
Cash from operations of $4.7M minus capital expenditures of $0.0 left free cash flow of -$4.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.